{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:28:04Z","timestamp":1793946484645,"version":"4.8.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.eclinm.2026.103820","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T21:35:36Z","timestamp":1773178536000},"page":"103820","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Once-daily oral ritlecitinib or brepocitinib versus placebo in patients with moderate-to-severely active Crohn's disease (PIZZICATO): an international, randomised, phase 2a trial"],"prefix":"10.1016","volume":"93","author":[{"given":"Severine","family":"Vermeire","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica R.","family":"Allegretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo Jong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Millie D.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9134-2070","authenticated-orcid":false,"given":"Jaroslaw","family":"Leszczyszyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2254-7771","authenticated-orcid":false,"given":"Stefan","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslaw","family":"Kierkus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulette D.","family":"Chandler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti","family":"Ramakrishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Peeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negin","family":"Shojaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Mahling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Banfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anindita","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy D.","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth E.","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2026.103820_bib1","series-title":"StatPearls. Treasure Island","first-page":"1","article-title":"Crohn disease","author":"Ranasinghe","year":"2024"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103820_bib2","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s12664-023-01430-z","article-title":"Trends of inflammatory bowel disease from the Global Burden of Disease Study (1990-2019)","volume":"43","author":"Dharni","year":"2024","journal-title":"Indian J Gastroenterol"},{"issue":"4","key":"10.1016\/j.eclinm.2026.103820_bib4","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1159\/000016938","article-title":"Impact of inflammatory bowel disease on health-related quality of life","volume":"17","author":"Casellas","year":"1999","journal-title":"Dig Dis"},{"key":"10.1016\/j.eclinm.2026.103820_bib5","article-title":"Treatment of inflammatory bowel disease: a comprehensive review","volume":"8","author":"Cai","year":"2021","journal-title":"Front Med"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103820_bib6","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"10.1016\/j.eclinm.2026.103820_bib7","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41575-020-0273-0","article-title":"JAK-STAT pathway targeting for the treatment of inflammatory bowel disease","volume":"17","author":"Salas","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.eclinm.2026.103820_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1089099","article-title":"JAK inhibitors: a new dawn for oral therapies in inflammatory bowel diseases","volume":"10","author":"Herrera-deGuise","year":"2023","journal-title":"Front Med"},{"issue":"12","key":"10.1016\/j.eclinm.2026.103820_bib9","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1021\/acschembio.6b00677","article-title":"Discovery of a JAK3-Selective inhibitor: functional differentiation of JAK3-Selective inhibition over pan-JAK or JAK1-Selective inhibition","volume":"11","author":"Telliez","year":"2016","journal-title":"ACS Chem Biol"},{"issue":"10","key":"10.1016\/j.eclinm.2026.103820_bib10","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1016\/j.cgh.2022.12.029","article-title":"Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe ulcerative colitis: results from a randomized, phase 2b study","volume":"21","author":"Sandborn","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"21","key":"10.1016\/j.eclinm.2026.103820_bib11","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib induction and maintenance therapy for Crohn's disease","volume":"388","author":"Loftus","year":"2023","journal-title":"N Engl J Med"},{"issue":"35","key":"10.1016\/j.eclinm.2026.103820_bib12","doi-asserted-by":"crossref","first-page":"9852","DOI":"10.1073\/pnas.1610253113","article-title":"Network pharmacology of JAK inhibitors","volume":"113","author":"Moodley","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.eclinm.2026.103820_bib13","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1002\/art.41316","article-title":"Efficacy and safety of PF-06651600 (Ritlecitinib), a novel JAK3\/TEC inhibitor, in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate","volume":"72","author":"Robinson","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.eclinm.2026.103820_bib14","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1021\/acschembio.9b00188","article-title":"PF-06651600, a dual JAK3\/TEC family kinase inhibitor","volume":"14","author":"Hua","year":"2019","journal-title":"ACS Chem Biol"},{"issue":"14","key":"10.1016\/j.eclinm.2026.103820_bib15","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s40265-023-01928-y","article-title":"Ritlecitinib: first approval","volume":"83","author":"Blair","year":"2023","journal-title":"Drugs"},{"issue":"10387","key":"10.1016\/j.eclinm.2026.103820_bib16","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","article-title":"Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b\u20133 trial","volume":"401","author":"King","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.eclinm.2026.103820_bib17","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jaad.2022.11.005","article-title":"Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: a randomized phase 2b clinical trial","volume":"88","author":"Ezzedine","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.eclinm.2026.103820_bib18","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1093\/ibd\/izab135","article-title":"Selective tyrosine kinase 2 inhibition for treatment of inflammatory bowel disease: new hope on the rise","volume":"27","author":"Danese","year":"2021","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"10.1016\/j.eclinm.2026.103820_bib19","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/art.42519","article-title":"Efficacy and safety of the TYK2\/JAK1 inhibitor brepocitinib for active psoriatic arthritis: a phase IIb randomized controlled trial","volume":"75","author":"Mease","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.eclinm.2026.103820_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2022.100156","article-title":"Safety and efficacy of ritlecitinib and brepocitinib in alopecia Areata: results from the crossover open-label extension of the ALLEGRO phase 2a trial","volume":"2","author":"King","year":"2022","journal-title":"JID Innov"},{"issue":"3","key":"10.1016\/j.eclinm.2026.103820_bib21","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300155","article-title":"Brepocitinib, Zimlovisertib, and Ropsacitinib in Hidradenitis Suppurativa","volume":"3","author":"Kimball","year":"2024","journal-title":"NEJM Evid"},{"issue":"4","key":"10.1016\/j.eclinm.2026.103820_bib22","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/jcph.1046","article-title":"The safety, tolerability, pharmacokinetics, and pharmacodynamics of a TYK2\/JAK1 inhibitor (PF-06700841) in healthy subjects and patients with plaque psoriasis","volume":"58","author":"Banfield","year":"2018","journal-title":"J Clin Pharmacol"},{"issue":"19","key":"10.1016\/j.eclinm.2026.103820_bib23","doi-asserted-by":"crossref","first-page":"8597","DOI":"10.1021\/acs.jmedchem.8b00917","article-title":"Dual inhibition of TYK2 and JAK1 for the treatment of autoimmune diseases: discovery of ((S)-2, 2-difluorocyclopropyl)((1 R, 5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl) amino) pyrimidin-4-yl)-3, 8-diazabicyclo [3.2. 1] octan-8-yl) methanone (PF-06700841)","volume":"61","author":"Fensome","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.eclinm.2026.103820_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.1037439","article-title":"Design and analysis of umbrella trials: where do we stand?","volume":"9","author":"Ouma","year":"2022","journal-title":"Front Med"},{"issue":"4","key":"10.1016\/j.eclinm.2026.103820_bib25","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1053\/j.gastro.2018.06.035","article-title":"Efficacy of ustekinumab for inducing endoscopic healing in patients with Crohn's disease","volume":"155","author":"Rutgeerts","year":"2018","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.eclinm.2026.103820_bib26","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/(SICI)1097-0258(20000330)19:6<811::AID-SIM390>3.0.CO;2-Z","article-title":"Minimum risk weights for comparing treatments in stratified binomial trials","volume":"19","author":"Mehrotra","year":"2000","journal-title":"Stat Med"},{"issue":"381","key":"10.1016\/j.eclinm.2026.103820_bib27","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1080\/01621459.1983.10477938","article-title":"Binomial confidence intervals","volume":"78","author":"Blyth","year":"1983","journal-title":"J Am Stat Assoc"},{"issue":"2","key":"10.1016\/j.eclinm.2026.103820_bib28","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2307\/3314658","article-title":"Refining binomial confidence intervals","volume":"14","author":"Casella","year":"1986","journal-title":"Can J Statistics"},{"issue":"4","key":"10.1016\/j.eclinm.2026.103820_bib29","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1111\/j.0006-341X.1999.01202.x","article-title":"Test-based exact confidence intervals for the difference of two binomial proportions","volume":"55","author":"Chan","year":"1999","journal-title":"Biometrics"},{"issue":"8","key":"10.1016\/j.eclinm.2026.103820_bib30","first-page":"72","article-title":"Oral ritlecitinib and brepocitinib in patients with moderate to severe acute ulcerative colitis: chronic therapy data from the VIBRATO unbrella study","volume":"10","author":"Sandborn","year":"2022","journal-title":"United European Gatroenterology"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103820_bib31","doi-asserted-by":"crossref","first-page":"7140","DOI":"10.1038\/s41598-022-10777-w","article-title":"Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database","volume":"12","author":"Hoisnard","year":"2022","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.eclinm.2026.103820_bib32","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41575-022-00722-7","article-title":"Risk minimization of JAK inhibitors in ulcerative colitis following regulatory guidance","volume":"20","author":"Danese","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.eclinm.2026.103820_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.103948","article-title":"Master protocols and other innovative trial designs in inflammation and immunology to expedite clinical drug development","volume":"29","author":"Peeva","year":"2024","journal-title":"Drug Discov Today"},{"issue":"2","key":"10.1016\/j.eclinm.2026.103820_bib34","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1053\/j.gastro.2024.10.009","article-title":"Placebo rates in Crohn\u2019s disease randomized clinical trials: an individual patient data meta-analysis","volume":"168","author":"Solitano","year":"2025","journal-title":"Gastroenterology"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026000672?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026000672?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:46:59Z","timestamp":1793944019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537026000672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":33,"alternative-id":["S2589537026000672"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.103820","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Once-daily oral ritlecitinib or brepocitinib versus placebo in patients with moderate-to-severely active Crohn's disease (PIZZICATO): an international, randomised, phase 2a trial","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.103820","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103820"}}